Reaction

Malignant Pleural Effusion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,661 reports · 75 co-occurring drugs

As of the last recalculation, Malignant Pleural Effusion appears in 1,661 FAERS reports alongside 75 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 42.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Gefitinib	30	42.4	42.5
Erlotinib Hydrochloride	38	38.9	39.0
Fulvestrant	85	33.9	34.0
Exemestane	51	30.7	30.8
Erlotinib	20	26.2	26.2
Pemetrexed	42	25.2	25.2
Pemetrexed Disodium	67	22.9	23.0
Osimertinib	56	22.6	22.7
Letrozole	92	19.8	19.8
Letrozole Tablets	65	17.6	17.6
Anastrozole Tablets	29	17.2	17.2
Anastrozole	47	16.5	16.5
Ado-Trastuzumab Emtansine	11	16.5	16.5
Bendamustine Hydrochloride	14	14.8	14.8
Lapatinib	18	14.7	14.7
Everolimus	55	14.0	14.0
Pembrolizumab	110	14.0	14.0
Everolimus Tablets	18	13.6	13.6
Carboplatin	127	13.5	13.5
Ribociclib	32	12.9	12.9
Crizotinib	13	12.9	12.9
Dexamethasone Sodium Phosphate	10	12.4	12.4
Bevacizumab	109	11.7	11.7
Rucaparib	8	11.4	11.4
Paclitaxel	85	11.3	11.3
Durvalumab	18	11.2	11.2
Paclitaxel (Aibumin-Bound)	70	11.1	11.1
Dronabinol	7	11.0	11.0
Lenvatinib	28	10.9	10.9
Bendamustine Hcl	13	10.6	10.6
Cabozantinib	39	10.4	10.4
Goserelin	11	10.3	10.3
Pazopanib Hydrochloride	22	10.3	10.3
Fam-Trastuzumab Deruxtecan-Nxki	8	10.0	10.0
Sorafenib	16	9.7	9.7
Docetaxel Anhydrous	48	9.2	9.2
Docetaxel	48	9.2	9.2
Nivolumab	68	9.1	9.2
Palbociclib	67	9.1	9.1
Capecitabine	64	9.1	9.1
Fosaprepitant Dimeglumine	9	8.2	8.2
Trifluridine And Tipiracil	7	8.2	8.2
Erythropoietin	13	8.0	8.0
Pertuzumab	17	7.9	7.9
Olaparib	13	7.8	7.8
Irinotecan Hydrochloride	8	7.8	7.8
Sunitinib Malate	23	7.4	7.4
Ipilimumab	25	7.4	7.4
Trametinib	14	7.3	7.3
Trastuzumab	39	7.3	7.3
Gemcitabine	22	7.1	7.1
Prochlorperazine	15	6.8	6.8
Ibrutinib	43	6.8	6.8
Prochlorperazine Maleate	5	6.8	6.8
Cisplatin	41	6.7	6.7
Gemcitabine Hydrochloride	28	6.7	6.7
Dabrafenib	11	6.6	6.6
Fluorouracil Cream, 0.5%	39	6.5	6.5
Ifosfamide	11	6.5	6.5
Fluorouracil	39	6.4	6.4
Niraparib	11	6.2	6.2
Atezolizumab	19	6.2	6.2
Brentuximab Vedotin	5	6.1	6.1
Axitinib	9	5.8	5.8
Brinzolamide	4	5.8	5.8
Alpelisib	4	5.8	5.8
Regorafenib	5	5.4	5.4
Doxorubicin	36	5.2	5.2
Polatuzumab Vedotin	4	5.1	5.1
Dasatinib	14	4.8	4.8
Abemaciclib	7	4.4	4.4
Selinexor	3	4.3	4.3
Avapritinib	4	4.1	4.1
Axicabtagene Ciloleucel	3	3.8	3.8
Methoxy Polyethylene Glycol-Epoetin Beta	3	3.4	3.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.